Document is current
Any future updates will be listed below
-
Authors
Kong, Jun
Tian, Ze
Deng, Dao-Xing
Mo, Xiao-Dong
-
Funding
Funding for this research was provided by:
the National Key Research and Development Program of China (2022YFA1103300)
the Natural Science Foundation of Beijing (Z230016)
- License Information
-
More Information
Article History
Received: 3 May 2025
Accepted: 18 August 2025
First Online: 29 September 2025
Declarations
:
: All the authors declare no competing interests.
: The use of iptacopan in these two patients was approved by the Institutional Review Board of Peking University People’s Hospital. At the time of iptacopan initiation, the first patient was unconscious; treatment consent was therefore provided by his next-of-kin, who later also gave consent for publication. The second patient provided written informed consent for both treatment and publication. All procedures were conducted in accordance with the Declaration of Helsinki.
